Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aura Biosciences Inc (NQ: AURA )

9.690 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5
Open 9.690
Bid (Size) 7.200 (1)
Ask (Size) 15.50 (2)
Prev. Close 9.690
Today's Range 9.690 - 9.690
52wk Range 5.990 - 12.35
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aura Biosciences Touts Promising Data From Eye Cancer Candidate
Aura Biosciences announced promising Phase 2 results for bel-sar in treating melanoma, achieving 80% tumor control. 
Via Benzinga
AURA Stock Earnings: Aura Biosciences Beats EPS for Q2 2024
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+7.31%
+7.31%
1 Month
+27.42%
+27.42%
3 Month
+39.83%
+39.83%
6 Month
+13.33%
+13.33%
1 Year
-0.31%
-0.31%

More News

Read More
AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024
Via InvestorPlace
AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023
Via InvestorPlace
Recap: Aura Biosciences Q4 Earnings
Via Benzinga
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
From Aura Biosciences Inc.
Via Business Wire
Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
Why Aura Biosciences Stock Hit A New 52-Week Low Today
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Aura Biosciences Announces Pricing of Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Aura Biosciences Announces Proposed Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
From Aura Biosciences, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Fall Off A Cliff This Month
Via Benzinga
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
From Aura Biosciences Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.